Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial of SENS-401 to prevent cisplatin-induced ototoxicity in a pediatric population

Trial Profile

A phase II trial of SENS-401 to prevent cisplatin-induced ototoxicity in a pediatric population

Planning
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs Arazasetron (Primary)
  • Indications Chemotherapy-induced damage
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 29 Jun 2018 According to a Sensorion media release, this trial is expected to begin in the coming weeks.
    • 12 Apr 2018 According to a Sensorion media release, this trial is expected to start at the beginning of 2019.
    • 24 Jan 2018 According to a Sensorion media release, phase 2 clinical program is expected to begin in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top